Galunisertib
- Generic Name
- Galunisertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19N5O
- CAS Number
- 700874-72-2
- Unique Ingredient Identifier
- 3OKH1W5LZE
- Background
Galunisertib has been used in trials studying the basic science and treatment of Glioma, Neoplasms, Solid Tumor, GLIOBLASTOMA, and Prostate Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Umbrella Biomarker-Guided Therapy in NPC
- Conditions
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 206
- Registration Number
- NCT04605562
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- The Netherlands Cancer Institute
- Registration Number
- NCT03470350
- Locations
- 🇳🇱
Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, Noord-Holland, Netherlands
Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
- Conditions
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 26
- Registration Number
- NCT03206177
- Locations
- 🇺🇸
Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Study of Galunisertib in Healthy Participants
- First Posted Date
- 2016-04-27
- Last Posted Date
- 2016-07-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 40
- Registration Number
- NCT02752919
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2019-08-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 37
- Registration Number
- NCT02734160
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇮🇹Ospedale Policlinico Giambattista Rossi, Borgo Roma, Verona, Italy
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer
- First Posted Date
- 2016-02-03
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT02672475
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-04-22
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 41
- Registration Number
- NCT02423343
- Locations
- 🇺🇸
H Lee Moffitt Cancer Center, Tampa, Florida, United States
🇪🇸Hospital Regional Universitario de Málaga, Malaga, Spain
🇪🇸Institut Catala d'Oncologia, Barcelona, Spain
A Study of Galunisertib on the Immune System in Participants With Cancer
- First Posted Date
- 2014-12-02
- Last Posted Date
- 2016-10-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 10
- Registration Number
- NCT02304419
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York City, New York, United States
A Study of Galunisertib in Participants With Myelodysplastic Syndromes
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 43
- Registration Number
- NCT02008318
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-06-14
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 170
- Registration Number
- NCT01373164
- Locations
- 🇺🇸
Florida Hospital Tampa HPG and Foregut Surgery, Tampa, Florida, United States
🇺🇸Ingalls Memorial Hospital, Harvey, Illinois, United States
🇪🇸For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.